Document is current
Any future updates will be listed below
-
Authors
Ademuyiwa, Foluso O. https://orcid.org/0000-0002-6766-2258
Northfelt, Donald W.
O’Connor, Tracey
Levine, Ellis https://orcid.org/0000-0003-2300-0524
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Tao, Yu
Hoog, Jeremy
Laury, Marie L.
Summa, Tracy
Hammerschmidt, Trish
Guo, Zhanfang
Frith, Ashley
Weilbaecher, Katherine
Opyrchal, Mateusz https://orcid.org/0000-0003-2454-7441
Aft, Rebecca
Clifton, Katherine
Suresh, Rama
Bagegni, Nusayba
Hagemann, Ian S. https://orcid.org/0000-0002-3855-9745
Iglesia, Michael D. https://orcid.org/0000-0002-0841-2144
Ma, Cynthia X.
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 16 December 2022
First Online: 6 January 2023
Competing interests
: The authors declare no competing interests but the following competing interests. F.O.A. receives research funding from Pfizer, Immunomedics, NeoImmuneTech, RNA Diagnostics, and Astellas, and fees from Teladoc Health, Pfizer, AstraZeneca, QED Therapeutics, Immunomedics, Cardinal Health, Athenex, Gilead, and Biotheranostics. C.X.M. receives research funding from Pfizer and Puma Biotechnology, Inc., and fees from AstraZeneca, Jacobio, Pfizer, Natera, Novartis, Inivata, Biovica, Athenex, Sanofi, Bayer, Seattle Genetics, Eisai.
